About SGN-CD123A

SGN-CD123A is an antibody-drug conjugate (ADC) targeted to CD123, a protein found on the surface of myeloid leukemia cells, including leukemic stem cells, in most patients with acute myeloid leukemia (AML). It uses our newest ADC technology, where the anti-CD123 antibody is attached with a stable linker to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer.

This antibody-drug conjugate (ADC) is designed to be stable in the bloodstream, and to release its cytotoxic agent once inside the CD123-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.


Phase 1 trial evaluating safety and antitumor activity of SGN-CD123A in patients with AML.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave